中国组织工程研究

中国组织工程研究 ›› 2011, Vol. 15 ›› Issue (5): 810-812.doi: 10.3969/j.issn.1673-8225.2011.05.012

• 肾移植 kidney transplantation • 上一篇    下一篇

西罗莫司在肾移植受者中的转换治疗

徐志强1，万有贵1，陈  博1，徐文英1，封玉宏1，周洪澜2   

  1. 1通辽市医院，内蒙古自治区通辽市 028200
    2吉林大学第一医院，吉林省长春市   130021
  • 收稿日期:2010-08-04 修回日期:2010-10-28 出版日期:2011-01-29 发布日期:2011-01-29
  • 通讯作者: 周洪澜，博士，主任医师，吉林大学第一医院，吉林省长春市 130021
  • 作者简介:徐志强★，男，1976年生，内蒙古自治区通辽市，蒙古族，2008年吉林大学毕业，硕士，主治医师，主要从事腔内泌尿外科及肾移植的研究。 chenmuxin@126.com

Conversion treatment using sirolimus for kidney transplant recipients

Xu Zhi-qiang1, Wan You-gui1, Chen Bo1, Xu Wen-ying1, Feng Yu-hong1, Zhou Hong-lan2   

  1. 1Tongliao Municipal Hospital, Tongliao  028200, Inner Mongolia Autonomous Region, China
    2First Hospital of Jilin University, Changchun  130021, Jilin Province, China
  • Received:2010-08-04 Revised:2010-10-28 Online:2011-01-29 Published:2011-01-29
  • Contact: Zhou Hong-lan, Doctor, Chief physician, First Hospital of Jilin University, Changchun 130021, Jilin Province, China
  • About author:Xu Zhi-qiang★, Master, Attending physician, Tongliao Municipal Hospital, Tongliao 028200, Inner Mongolia Autonomous Region, China chenmuxin@126.com

PDF

366

被引次数

6

摘要：

背景：传统的钙调磷酸酶抑制剂能导致慢性移植肾肾病的发生，新型免疫抑制剂西罗莫司的出现就为替换这一治疗方案提供了可能。
目的：验证西罗莫司在肾移植后受者中转换治疗的临床效果及其安全性。
方法：对同种异体肾移植后以口服钙调磷酸酶抑制剂为主的60例受者，进行以西罗莫司为主的转换治疗，观察转换后6个月内临床效果、安全性和不良反应。
结果与结论：西罗莫司转换治疗后6个月内急性排斥反应发生率为13.3%。因慢性移植肾肾病进行药物转换的受者，转换后肾功能改善；其他转换后移植后肝损害及高血糖有所改善。结果提示西罗莫司在转换治疗时疗效优于钙调磷酸酶抑制剂。

关键词: 西罗莫司, 钙调磷酸酶抑制剂, 肾移植, 免疫抑制剂, 安全性

Abstract:

BACKGROUND: Traditional calcium the phosphoric acid enzymes inhibitors can result in a chronic renal transplants kidney disease. Vaccination sirolimus inhibitors provide new substitution for the treatment.
OBJECTIVE: To verify the efficacy and safety of conversion treatment of sirolimus for kidney transplant recipients.
METHODS: Sixty eligible kidney transplant recipients treated with calcineurin inhibitor as main immunosuppressives were converted to sirolimus. The clinical outcome, complications and side effects were observed.
RESULTS AND CONCLUSION: Eight recipients (13.3%) experienced acute rejection. The renal functions of recipients with chronic renal transplants kidney disease were improved after conversion treatment. The liver damage or hyperglycemia also improved in other recipients. The results demonstrated that sirolimus is superior to calcineurin inhibitor in conversion treatment.

中图分类号: